- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
New agent proves its value in breast scintigraphy scans
Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine
Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine.
Researchers at the Karolinska Institute of Stockholm and the Norwegian Radiumhospital in Oslo tested Tc-99m NC100692 in a study of 16 patients with suspicious mammograms and four patients with benign breast lesions 6 mm or larger. Imaging with the new agent detected 19 of 22 malignant lesions.
No serious adverse events were encountered with the new agent, though mild side effects occurred in five patients. Tc-99m sestamibi has been used in the past to support mammography, but its sensitivity never went beyond 50% for lesions smaller than 12 mm. Tc-99m NC100692 showed 100% sensitivity for lesions 10 mm or larger.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
